Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

Esophageal squamous cell carcinoma (ESCC) is a deadly cancer with particularly high prevalence in East Asia. While ...

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

The three major histopathological subtypes of RCC are clear cell carcinoma (ccRCC), papillary carcinoma (pRCC), and chromophobe renal cell carcinoma (chrRCC). Studies have reported that ccRCC has the ...

Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer, marked by high molecular heterogeneity and limited responsiveness to targeted or immune therapies.

Metastasis is a major cause of mortality in patients with lung adenocarcinoma (LUAD), with the premetastatic niche (PMN) playing a crucial role in LUAD metastasis. However, the mechanisms underlying ...